Opioid Packaging: Is Non-Inferiority Enough For A New Claim?
Executive Summary
Industry exec suggests new packages need be merely no worse than the classic amber vial to gain a claim, but US FDA says packaging intended to fight abuse should be better.
You may also be interested in...
Hahn Confirmation Hearing: Pharma May Be Left Parsing Non-Rx Questions For Policy Clues
US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.
Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
In his first speech to an outside group, Sharpless strikes a collaborative tone, saying he expects to listen to the advice of the FDA bar, as well as his own experts.
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also to support many initiatives in last year's budget request.